文献速递牙体牙髓病儿童口腔

再生牙髓治疗中根管内药物对恒牙坏死未成熟牙疗效的系统评价与间接比较Meta分析

The Efficacy of Intracanal Medicaments Within the Regenerative Endodontic Procedures on Permanent Necrotic Immature Teeth: Systematic Review and Naïve Indirect-Comparison Meta-Analysis.
PubMed 文献 · Int Endod J · 2026-03-12

TAP和CH的汇总成功率分别为96.7%和97.4%,二者等效,且均优于DAP(84.2%);证据质量TAP和CH为高,DAP为低。

要点

  • TAP与CH在REP中1年成功率等效,均优于DAP。
  • TAP成功率96.7%,CH为97.4%,DAP为84.2%。
  • 证据质量TAP和CH为高,DAP为低。

核心结论

  • 在REP中,TAP和CH作为根管内药物在1年随访时消除感染和促进根尖周愈合方面等效,且均优于DAP。

研究设计与样本

  • 检索MEDLINE、Scopus、Embase、Web of Science、Google Scholar(截至2025年12月),使用RoB2评估偏倚风险,GRADE评估证据质量。

主要发现

  • TAP汇总成功率96.7%(95%CI 94.8%-98.0%),DAP为84.2%(95%CI 73.2%-92.0%),CH为97.4%(95%CI 93.9%-99.1%)。
  • TAP-DAP成功率差异12.5%(95%CI 2.8%-22.1%),显示TAP优效;TAP-CH差异-0.7%(95%CI -0.9%-2.5%),显示等效;CH-DAP差异13.2%(95%CI 3.3%-23.0%),显示CH优效。
  • GRADE证据质量:TAP和CH为高,DAP为低(因研究数量少、样本量小导致不精确性)。

关键数值与推荐

  • 成功率定义为1年牙齿存活且根尖周愈合、无病理症状和体征。
  • 等效性范围设定为-2.5%/+2.5%。

临床怎么用

  • 在恒牙坏死未成熟牙的REP中,可优先选择TAP或CH作为根管内药物,二者1年成功率等效。
  • DAP的成功率较低,应谨慎使用。

局限性

  • 缺乏协议间的直接比较和共同对照,无法进行更稳健的分析。
  • 次要分析因样本量小导致统计检验效能低。
  • DAP证据质量低,主要因研究数量少和样本量小导致的不精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to estimate and compare the 1-year clinical success rates of triple antibiotic paste (TAP), double antibiotic paste (DAP), calcium hydroxide (CH) within regenerative endodontic procedures (REPs) on permanent necrotic immature teeth. MATERIALS AND METHODS: Trials investigating REP success were searched through MEDLINE, Scopus, Embase, Web of Science, GOOGLE Scholar (last update December 2025). Primary study quality was evaluated through the revised Cochrane Risk of Bias tool for Randomised Trials (RoB2). Pooled success rates with 95% confidence intervals (95% CIs) were assessed. Heterogeneity was investigated with the Cochran's Q and quantified with I2: The random-effects model was preferred to the fixed-effect model for I2 > 50%. Sensitivity (study quality, publication bias, study inclusion) and subgroup (scaffold type, world Region) analyses were made. The differences in pooled success rates between protocols were assessed and were evaluated using an equivalence range of -2.5%/+2.5%. The GRADE system was employed to evaluate the Quality of Evidence of the pooled success rates. RESULTS: Twenty-four studies of average quality were included involving 544, 64, 183 patients, for TAP, DAP, CH, respectively. The pooled success rates (tooth survival after 1 year with periapical healing, absence of signs and symptoms of pathology) were TAP 96.7% (95% CI, 94.8%-98.0%), DAP 84.2% (95% CI, 73.2%-92.0%), CH 97.4% (95% CI, 93.9%-99.1%). The pooled differences in success rates were TAP-DAP 12.5% (95% CI, 2.8%-22.1%, TAP superiority demonstrated), TAP-CH -0.7% (95% CI, -0.9%-2.5%, TAP/CH equivalence demonstrated), CH-DAP 13.2% (95% CI, 3.3%-23.0%, CH superiority demonstrated). Secondary analyses corroborated these results, although the overall statistical test power was low due to small sample sizes. The GRADE quality of evidence was high for TAP and CH, and low for DAP, due to substantial imprecision attributed to the small number of studies with small sample sizes. CONCLUSIONS: The lack of direct comparisons between protocols and of a common comparator did not allow for more robust analyses. Nevertheless, the use of TAP and CH as intracanal medicament within REPs resulted equivalent in eradicating the infection and promoting periapical healing in permanent necrotic immature teeth at 1-year follow up, and these protocols resulted superior over DAP. REGISTRATION: PROSPERO registration number: CRD42023484189.

来源:Int Endod J,查看原文。版权归原作者所有。

引用

  1. Alovisi M, Arduino PG, Petti S, et al. The Efficacy of Intracanal Medicaments Within the Regenerative Endodontic Procedures on Permanent Necrotic Immature Teeth: Systematic Review and Naïve Indirect-Comparison Meta-Analysis. Int Endod J. 2026. PMID: 41815050. doi:10.1111/iej.70135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。